Aims: To determine the seroprevalence of Toxoplasma gondii (T. gondii) in women from Aljalla Maternity and Gynaecology Hospital (AMGH) and to evaluate the association between the infection and potential risk factors. Methods: A cross-sectional study was conducted at AMGH in Tripoli during the year 2012. Data on potential risk factors were collected by a structured questionnaire and results of the test. The output data of questionnaire were used to assess potential risk factors for positive outcome. All sera (n = 500) was screened against ToxoG, by using the Vidas machine automated enzyme-linked florescent immunoassay. The association between the outcome variables and its potential risk factors were screened in a multivariate analysis. A p-value < 0.05 was considered to be significant. Results: The overall seroprevalence was estimated to be 50.8% with 95% confidence interval (CI) (46.42%–55.18%). The results revealed that T. gondii infection is highly prevalent, and eating habits (consuming raw meat and/or raw vegetables or fruits) were highly significant associated in multivariable analysis. Expectedly, a significantly [odds ratio (OR):1.712; p =
Abdusalam Sharef Abdusalam Mahmoud(1-2019)

An experiment was conducted to study chlorpyrifos chronic toxicity in broilers and the protective effect of vitamin C. Oral administration of 0.8 mg/kg body weight (bw) (1/50 LD50) chlorpyrifos (Radar®), produced mild diarrhea and gross lesions comprised of paleness, flaccid consistency and slightly enlargement of liver. Histopathologically, chlorpyrifos produced degenerative changes in various organs. Oral administration of 100 mg/kg bw vitamin C partially ameliorated the degenerative changes in kidney and heart. There was insignificant alteration in biochemical and haematological profiles. It is concluded that supplementation of vitamin C reduced the severity of lesions induced by chronic chlorpyrifos toxicity in broilers.
Abdulwahab Kammon(1-2022)

Live vaccines against fowlpox virus, which causes moderate pathology in poultry and is the type species of the Avipoxvirus genus, were developed in the 1920s. Development of recombinant fowlpox virus vector vaccines began in the 1980s, for use not only in poultry, but also in mammals including humans. In common with other avipoxviruses, such as canarypox virus, fowlpox virus enters mammalian cells and expresses proteins, but replicates abortively. The use of fowlpox virus as a safe vehicle for expression of foreign antigens and host immunomodulators, is being evaluated in numerous clinical trials of vaccines against cancer, malaria, tuberculosis and AIDS, notably in heterologous prime–boost regimens. In this article, technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector in poultry and mammals are reviewed.
Ibrahim Eldaghayes(1-2014)